Autism Protocol #
How does our protocol differ from current autism treatments? #
Most current treatments for autism are designed to help children build new skills and minimize the effect their symptoms have on their lives.
Unlike those existing therapies, the Neurocytonix protocol is designed to help the body form new neural connections within the brain. We believe these new pathways may make social and behavioral tasks easier for children with autism, but more research is needed.
Autism Clinical Trials #
Previous Open Label Study #
Beginning in 2024, NeuroCytonix held an open label study based in Monterrey, Mexico, to investigate the use of our protocol to treat autism.
Preliminary results suggest that the protocol may help increase social function, improve attention, and decrease repetitive behaviors in children with autism
Randomized Controlled Trial #
Beginning in 2026, NeuroCytonix is launching a new randomized, controlled clinical trial of the autism protocol. Based in Rockville, Maryland, the study will enroll 256 children with autism. It is expected to complete within the next 3-5 years.
- Inclusion criteria
- Diagnosed with autism according to DSM-5 criteria
- Age range 3-12 years
- Autism severity grade 1 or 2
- Participants must be verbal, medically stable, and able to receive an MRI
- Trial design
- 1:1 randomization to receive the therapy or a placebo (50% will receive active therapy, while 50% will receive a sham/ placebo treatment); neither participants nor study clinicians will know which treatment the participant is receiving
- Participants will receive the NeuroCytotron treatment for 1 hour per day for 28 days
- Participants will receive comprehensive medical evaluations, EEGs, MRI scans, and autism symptom assessment before treatment, immediately after the treatment, and then one month and two months after treatment completion
NeuroCytonix Mexico Clinical Research Center #
Discover the future of medical research at our state-of-the-art clinical research center.
